Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vision, Ocular Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Bioness Integrated Therapy System (BITS) Touch Screen Technology to Improve Field Awareness

NCT04930822
View directory record Official record
Conditions
Stroke, Neurologic Disorder, Traumatic Brain Injury, Acquired Brain Injury
Interventions
Table Top Visual Intervention, Bioness Integrated Therapy System Visual Intervention
Other · Device
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Electric Stimulation of the Eye to Improve Vision After Trauma

NCT02019927
View directory record Official record
Conditions
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
Interventions
Transcorneal Electrical Stimulation, Sham
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 17, 2026, 3:52 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 17, 2026, 3:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Validation of Clinical Outcome Measures Specific to mTBI-Related Oculomotor Disorders

NCT07282691
View directory record Official record
Conditions
MTBI - Mild Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Salus University
Other
Eligibility
18 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 17, 2026, 3:52 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Comparison of Latanoprost Vs. Timolol

NCT00579969
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Not applicable Interventional

Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

NCT03492541
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops

NCT01925391
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure, Anesthesia
Interventions
Tono-pen XL Applanation tonometer + Ocu-film +
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 18 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

NCT00315328
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Patching, Near activities
Drug · Device · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 2 Interventional

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT02179008
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Chandler, Arizona • Artesia, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

NCT02829268
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
Interventions
dantrolene sodium
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

Treatment of Failing Blebs With Ranibizumab

NCT00570726
View directory record Official record
Conditions
Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
6 participants
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 17, 2026, 3:52 AM EDT
Not listed Phase 1 Interventional

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 17, 2026, 3:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retinal Fundus Camera Evaluation

NCT02293174
View directory record Official record
Conditions
Normal Healthy Subjects With no Known Ocular Diseases
Interventions
Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 17, 2026, 3:52 AM EDT
Completed No phase listed Observational

Color Vision as a Measure for Inherited Retinal Diseases

NCT01878032
View directory record Official record
Conditions
Healthy Volunteer, Retinal Disease, Inherited Retinal Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Phase 2 Interventional

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

NCT00074191
View directory record Official record
Conditions
Lymphoma
Interventions
cytarabine, dexamethasone, lomustine, methotrexate, procarbazine hydrochloride
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 17, 2026, 3:52 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of a Daily Wear Frequent Replacement Silicone Hydrogel Lens

NCT03920280
View directory record Official record
Conditions
Refractive Errors
Interventions
LID015385 contact lenses, Comfilcon A soft contact lenses, CLEAR CARE
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
8
States / cities
Maitland, Florida • Orlando, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 17, 2026, 3:52 AM EDT